ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
If you purchased or acquired securities in Actinium between October 31, 2022 and August 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - May 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Actinium Pharmaceuticals, Inc. ('Actinium' or the 'Company') (NYSE: ATNM) and reminds investors of the May 26, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/6455/252477_73d0ab89642d68b8_001full.jpg ]
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company's data from Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
As the truth about Actinium's business reached the market, the price of Actinium's stock suffered significant declines, harming investors. For example, on the morning of August 5, 2024, before the market opened, when Actinium issued a press release providing, among other things, a regulatory update on the planned BLA filing and the future plans for Iomab-B in the U.S. Specifically, the press release revealed the Company would need to conduct an additional clinical trial to further support the Company's BLA filing. On this news, the price of Actinium's common stock plummeted $3.69, or nearly 60%, to close at $2.48, on unusually high trading volume.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Actinium's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Actinium Pharmaceuticals, Inc. class action, go to www.faruqilaw.com/ATNM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252477
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Digital Trends
a minute ago
- Digital Trends
RTX 40-series GPUs just got smoother gameplay with Nvidia's latest update
Out with the old, in with the new. According to Board Channels, Nvidia has now halted production for nearly all of its best graphics cards as it shifts focus to the RTX 50-series. Only one GPU remains in production, and some of the cards that are the most in demand are no longer being produced. Nvidia hasn't officially announced that it's sunsetting the RTX 40-series, but we've been hearing more and more reports that imply that might be the case. The RTX 4090 was among the first cards to go out of production, and the discontinuation appears to have immediately affected the markets. Nvidia's behemoth flagship was hard to come by at the best of times, and now, as no more new units are being produced, it's safe to assume that this situation won't improve. The cheapest RTX 4090 I could find on Amazon costs nearly $2,000, but you can still snag one for $1,900 at Newegg .
Yahoo
29 minutes ago
- Yahoo
Wall Street sees stock market rotation charting 'healthiest path' to new highs
The stock market's rally to record highs has started to suggest some investors see life outside of the Big Tech names that have defined markets since 2023, as lagging sectors like Health Care (XLV) and Homebuilders (XHB) — as well as out-of-favor investments like small- and mid-cap stocks — have played a larger role in this summer's move. And some strategists see this rotation as an early sign that an even healthier market dynamic could be emerging. Scott Chronert, managing director of US equity strategy at Citi, sees this broader participation as framing out "two parallel paths" for the S&P 500 — one led by the AI-fueled growth giants and the other driven by more traditional sectors tied to the economy. "The simple answer is that we see ongoing Mega Cap Growth participation, if not leadership, but with fundamental and performance broadening creating a more durable structural setup," he said on Friday. "The healthiest path to higher index levels is a combination of Growth/Tech leadership persisting but with other areas of the market additive more so than has been the case this past year." Data from Bespoke Investment Group published Friday noted investors last week showed signs of moving out of 2025's biggest winners and into less-loved pockets of the market. Over the middle three trading days last week, Bespoke's work found stocks in the worst-performing decile this year among S&P 1500 companies were up an average of 6.7%; the best performers were up less than 1% over the same period. "When momentum names stall or sell-off, it can really hit the major indices hard if no other areas of the market are there to pick up the slack," Bespoke said. "But [last] week, the year's worst performers finally saw some buying interest as investors rotated across the market instead of out of it." Ed Yardeni of Yardeni Research added that rising expectations for a September Fed rate cut helped fuel the shift, sparking a rotation from growth to value and from large caps to small- and mid-cap stocks. "We certainly welcome such a broadening," he wrote in a Sunday note to clients. 'Significant headwinds' remain Sean Simonds, US equities strategist at UBS, described the current broadening setup as "a mixed bag," noting that AI-driven momentum is starting to spill into other adjacent areas like software, power, and re-shoring. Simonds added that after a wave of downward earnings revisions earlier this year, earnings breadth has also shown signs of improving. However, areas such as consumer and healthcare remain weaker, even if the outlook there has turned "less negative." Gerry Fowler, head of European equity strategy at UBS, added that small-cap stocks in particular depend on a 'Goldilocks' scenario in which the Fed manages to cut rates without spooking markets. "If Powell is able to stay out of the headlines and deliver the September cut in line with expectations, there is room for the broader market to remain quite healthy," Fowler said. "On either side of Goldilocks, you've got significant headwinds for the Russell 2000." Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments Fowler's cautious note echoes a broader concern on Wall Street, which is that signs of rotation among styles and sectors overstate the extent to which this shift sees investors actually preferring to put more money behind new themes. DataTrek Research noted in a recent report that just two of the S&P 500's 11 sectors — Technology (XLK) and Industrials (XLI) — have outperformed since the index's April lows. The firm also noted that the top 20 names in the index, or nearly half the S&P 500 on a market cap basis, are up more than 40% on average over that period. That concentration means the durability of the rally may hinge on whether new pockets of strength can sustain recent momentum. Looking ahead, Simonds cautioned that momentum could stall if earnings expectations fade or if the Fed delivers a surprise that clashes with market expectations. "There's still the possibility of earnings expectations slowing into the second half of this year and first half of next year," he said. 'And any disappointment out of Jackson Hole or into the September Fed meeting will definitely take some wind out of the sails as well." Allie Canal is a Senior Reporter at Yahoo Finance. Follow her on X @allie_canal, LinkedIn, and email her at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Statistics Canada to release July inflation report this morning
OTTAWA — Statistics Canada is set to release its consumer price index report for July this morning. A poll of economists provided by LSEG Data & Analytics expects the annual inflation rate dipped to 1.8 per cent in July. That's down from 1.9 per cent year-over-year in June. Economists are hoping the report will provide further clarity on how tariffs are affecting the economy. The Bank of Canada will be paying particular attention to core inflation metrics, which strip out more volatile categories from the readings, as they've been stubbornly strong. The central bank's recent summary of deliberations from its July 30 interest rate decision showed members thought the impact of tariffs on consumer prices so far has been modest. This report by The Canadian Press was first published Aug. 19, 2025. The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
